Dr Reddy?s launches generic version of Ciprodex Otic Suspension, USP in US market

Hyderabad, Dr Reddy’s Laboratories Limited along with its subsidiaries together on Tuesday announced the launch of Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3 per cent and dexamethasone 0.1 per cent) Otic Suspension, approved by the US Food and Drug Administration (USFDA).”We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” Mr Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories said.”At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form,” he added.The Ciprodex brand had US sales of approximately USD 453 million MAT for the most recent 12 months ending in June 2020 according to IQVIA Health.Dr Reddy’s Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle, a company statement here said.